佐剂重组带状疱疹疫苗对带状疱疹的长期保护作用：初次接种后长达10年的中期疗效、免疫原性和安全性结果
Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination.
作者信息
Strezova Ana, Diez-Domingo Javier, Al Shawafi Kamal, Tinoco Juan Carlos, Shi Meng, Pirrotta Paola, Mwakingwe-Omari Agnes
机构信息
GSK, Rixensart, Belgium.
FISABIO Fundación para el Fomento Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Valencia, Spain.
出版信息
Open Forum Infect Dis. 2022 Oct 23;9(10):ofac485. doi: 10.1093/ofid/ofac485. eCollection 2022 Oct.
Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years.
在接种重组带状疱疹疫苗（RZV）约10年后，ZOE - 50/70试验的这项随访研究的中期分析表明，其对带状疱疹的疗效仍然很高。此外，安全性在临床上仍然可以接受，这表明RZV在≥50岁人群中的临床益处可持续长达10年。
Zotero 插件